Stockscreener 앱 받기
0.9435
6.58%
-0.0665
시장 영업 전:
.95
0.0065
+0.69%
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance
Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World
Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World
Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register
Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks
Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada
Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - TradingView
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating - Investing.com India
Y Intercept Hong Kong Ltd Invests $58,000 in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics: Q4 Earnings Snapshot - mySA
Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses - TipRanks
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - Marketscreener.com
Fate Therapeutics shares rise as Q4 revenue tops estimates By Investing.com - Investing.com South Africa
Fate Therapeutics shares rise as Q4 revenue tops estimates - Investing.com
Fate Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics, Inc Q4 Loss Misses Estimates - Nasdaq
Fate Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 04:13 pm EST - Marketscreener.com
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating - Defense World
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Fate Therapeutics (FATE) Expected to Announce Earnings on Monday - MarketBeat
Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average PT from Analysts - Armenian Reporter
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance
Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat
FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - accessnewswire.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of “Hold” from Analysts - Defense World
What is Leerink Partnrs’ Estimate for FATE Q1 Earnings? - Defense World
Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
1.39%
0.55%
자본화:
|
볼륨(24시간):